PAR technology provides point-of-sale solutions to restaurants and retail outlets. Anyone with experience with these products? Seems like an interesting way to play a retail rebound because it's doing so great right now when (smaller) retailers are on the brink of bankruptcy.
Every time they add a $5 an hour crackhead the market cap goes up $3 billion. It seems. Ok maybe they're not crackheads, but it seems it is below-median workers that they attract. edit: My apologies for the above outburst. I have to realize there is a market for below-median workers too. I think my problem with "the story" is this is not really anything special. Just filling a void in the market I guess. But hey the gig economy! aka another excuse to not pay benefits...but if workers are taking it... This company is becoming profitable already and still growing strongly. I am seeing a 77%(!) growth rate at stockrow.com. It has got strong momentum. Can't argue with that.
ZS reports next week (25th). The New National Defense; ZS has a market cap of only $30 billion while the old national defense companies (Raytheon, Lockheed Martin) are $100 billion each.
How do I know the freelancer's hourly rate? Trick question! On Fiverr, you pay freelancers per project, not per hour. The price for the service and everything included is clearly stated in their project proposal.
What interests me most in the upcoming week is the general market direction. It could go either way really, in my opinion. As far as individual stocks are concerned, I still like to play the "new space age" theme. AVAV and LORL have been on a tear recently. I added ORBC on the pullback last week. It will either be at $10 or like $7.50 in 1-2 weeks. Earnings on Wednesday before the bell. Does anyone have any other space recommendations?
Investors might want to bet on Acasti Pharma (ACST), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Therefore, the Zacks rating upgrade for Acasti basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. For the fiscal year ending March 2021, this biopharmaceutical company is expected to earn -$0.19 per share, which is a change of 17.4% from the year-ago reported number. Analysts have been steadily raising their estimates for Acasti. Over the past three months, the Zacks Consensus Estimate for the company has increased 7.5%.
GTLS has got some support here Another natural gas play is BE which came back to test the 34 week ema (not shown).
